- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00920842
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant
Metabolic Syndrome Following Transplant for Leukemia
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood leukemia who have undergone stem cell transplant may help doctors learn more about the disease and the long-term effects of leukemia treatment. It may also help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone stem cell transplant.
Visão geral do estudo
Status
Descrição detalhada
OBJECTIVES:
- To determine the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) and compare the extent to which prevalence is higher in HSCT survivors than in age- and gender-matched population norms derived from the Third National Health and Nutrition Examination Survey (NHANES III).
- To evaluate the relationship between insulin resistance and risk factors associated with metabolic syndrome (e.g., hypertension, obesity, hyperinsulinemia, and dyslipidemia) as measured by euglycemic insulin clamp, fasting serum insulin, glucose, lipids (total cholesterol, triglycerides, LDL-C, and HDL-C), blood pressure and anthropometric measurements, and DEXA scan in these patients and compare to age- and gender-matched population norms.
- To assess the extent to which prevalent obesity and insulin resistance are correlated with other factors that have been identified in the causal pathway associated with the development of metabolic syndrome and that may be altered after HSCT, including growth hormone secretion, adipokines (adiponectin and leptin), and inflammatory mediators (interleukin-6, tumor necrosis factor-α, and C-reactive protein).
- To evaluate the association of metabolic syndrome and early signs of impaired endothelial function and cardiovascular changes.
- To evaluate health behaviors related to prevention of cardiovascular disease, diabetes, and obesity, including a physical activity assessment, a dietary assessment, and a health knowledge assessment that will be used in the analyses of metabolic syndrome, growth hormone deficiency, and indicators of cardiovascular disease.
OUTLINE: Patients are stratified according to post-transplant follow-up period (2-9 years vs 10-15 years vs > 15 years).
Patients and their siblings undergo physical examination, a review of medical and family history, and blood pressure and anthropometric measurements. Patients and their siblings also undergo blood sample collection for laboratory studies (including analysis of C-reactive protein and CBC; lipid profile and triglycerides; leptin and adipokines; free thyroxine, TSH, IGF1, IGF3, and LH; and estradiol [females] or testosterone [males]); urine sample collection for microalbumin determination; and other study procedures (including euglycemic insulin clamp study; body composition and bone density [DEXA] study; bone-age x-ray [for patients < 18 years of age]; and vascular studies). Patients also undergo growth hormone stimulation testing.
Patients and their siblings complete questionnaires about their physical activity, dietary habits, and health knowledge.
PROJECTED ACCRUAL: A total of 193 childhood leukemia survivors and 193 healthy siblings will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98105
- Clinical Research Center - Seattle Children's Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Survivor of childhood leukemia, meeting all of the following criteria:
- 21 years of age and under at diagnosis
- Has undergone hematopoietic stem cell transplantation (HSCT) at Fairview University Medical Center or Fred Hutchinson Cancer Research Center ≥ 2 years ago
- Disease in remission
- Healthy sibling of a childhood leukemia survivor
PATIENT CHARACTERISTICS:
- Not pregnant
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Comparison of the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) with age- and gender-matched controls
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Comparison of insulin resistance in patients with age- and gender-matched controls
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Correlation between insulin sensitivity and risk factors associated with metabolic syndrome
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Influence of time since transplant on insulin resistance
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Peak growth hormone secretion in patients with insulin resistance and in those without
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Growth hormone deficiency in patients with metabolic syndrome and in those without
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Association of interleukin-6, tumor necrosis factor-α, C-reactive protein, and leptin with insulin resistance and central obesity
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Correlation of adiponectin with insulin resistance and central obesity
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Differences in markers for endothelium dysfunction and early indicators of cardiovascular disease
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
|
Difference in important health behaviors related to obesity and cardiovascular disease between patients with metabolic syndrome and those without
Prazo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: K S Baker, MD, MS, Fred Hutchinson Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- leucemia linfocítica crônica estágio I
- sobrevivente de cancer
- leucemia linfoblástica aguda infantil em remissão
- leucemia mielóide aguda infantil em remissão
- leucemia mielomonocítica juvenil
- Leucemia Mielóide Crônica na Infância
- síndrome metabólica
- efeitos a longo prazo secundários à terapia do câncer em crianças
- leucemia linfocítica crônica estágio II
- leucemia linfocítica crônica estágio III
- leucemia linfocítica crônica estágio IV
- complicações cardiovasculares
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IR 7141
- P30CA077598 (Concessão/Contrato do NIH dos EUA)
- UMN-2003NT063
- CDR0000642276 (Identificador de registro: NCI)
- IR-6980 (Outro identificador: Former FHCRC IRB ID)
- FHCRC-2357.00 (Outro identificador: Former FHCRC ID)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .